AntriaBio Announces Selection of Lead Oral Plasma Kallikrein Inhibitor Candidates for the Treatment of Diabetic Retinopathy, Diabetic Macular Edema and Hereditary Angioedema

LOUISVILLE, Colo., Oct. 17, 2017 (GLOBE NEWSWIRE) — AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing therapies to address significant unm…Read More »

AntriaBio Appoints Nektar Therapeutics CFO to its Board of Directors

LOUISVILLE, Colo., Oct. 09, 2017 (GLOBE NEWSWIRE) — AntriaBio, Inc. (“AntriaBio” or the “Company”) (OTCQB:ANTB), a biopharmaceutical company specializing in the development of innovative drug therapi…Read More »

AntriaBio Appoints Dr. Robert Bhisitkul to its Scientific Advisory Board

LOUISVILLE, Colo., Oct. 04, 2017 (GLOBE NEWSWIRE) — AntriaBio, Inc. (“The Company”) (OTCQB:ANTB), a biopharmaceutical company focused on developing platform technologies to target significant unmet m…Read More »

AntriaBio and ActiveSite Pharmaceuticals Announce License and Development Agreement for Plasma Kallikrein Inhibitors

LOUISVILLE, Colo., Aug. 07, 2017 (GLOBE NEWSWIRE) — AntriaBio, Inc. (“AntriaBio”) (OTCQB:ANTB) and ActiveSite Pharmaceuticals (“ActiveSite”) today announced that AntriaBio has exclusively licensed Ac…Read More »

AntriaBio Announces First Patient Dosed in Phase 1 Clinical Study of AB101

LOUISVILLE, CO — (Marketwired) — 07/25/17 — AntriaBio, Inc. (“AntriaBio or the “Company”) (OTCQB: ANTB) , a biopharmaceutical company specializing in the development of innovative drug therapies to…Read More »

Forward Looking Statements

This release, like many written and oral communications presented by AntriaBio, Inc., and our authorized officers, may contain certain forward-looking statements regarding our prospective performance and strategies within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and are including this statement for purposes of said safe harbor provisions. Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, and expectations of the Company, are generally identified by use of words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "seek," "strive," "try," or future or conditional verbs such as "could," "may," "should," "will," "would," or similar expressions. Our ability to predict results or the actual effects of our plans or strategies is inherently uncertain. Accordingly, actual results may differ materially from anticipated results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Except as required by applicable law or regulation, AntriaBio undertakes no obligation to update these forward-looking statements to reflect events or circumstances that occur after the date on which such statements were made.

This Blog is official and sanctioned by AntriaBio, Inc. | See Disclaimer and Terms of Use

Get AntriaBio, Inc. Blog Post Alerts